GlassScriptPhysician profile
Joseph F John
NPI 1598866592
$1,948.52
in general payments reported to CMS, 2019-2025
19 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $137 · 2021: $162 · 2022: $182 · 2023: $263 · 2024: $365 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $337.93 | 2020-2025 | Cabenuva, Dovato, Rukobia |
| Merck Sharp & Dohme LLC | $238.07 | 2019-2025 | Pifeltro, Capvaxive, Gardasil 9 |
| Gilead Sciences, INC. | $234.92 | 2019-2024 | |
| Abbvie INC. | $229.89 | 2021-2025 | |
| Melinta Therapeutics, LLC | $183.06 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Allergan, INC. | $133.46 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $103.56 | 2019-2025 | Nuzyra |
| Insmed, INC. | $74.93 | 2019-2024 | Arikayce |
| Shionogi INC | $72.36 | 2020-2022 | |
| Theratechnologies INC. | $66.38 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $63.22 | 2023-2025 | Rebyota |
| Xeris Pharmaceuticals, INC. | $57.77 | 2023-2024 | Keveyis |
| Astellas Pharma US INC | $47.98 | 2023 | Cresemba |
| Cumberland Pharmaceuticals, INC. | $24.11 | 2023 | Vibativ |
| Grifols USA, LLC | $21.70 | 2024 | Xembify |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gc Biopharma USA, INC. | $19.20 | 2025 | Alyglo |
| Napo Pharmaceuticals INC | $16.31 | 2023 | Mytesi |
| Tetraphase Pharmaceuticals, INC. | $12.58 | 2019 | |
| Vyera Pharmaceuticals, LLC | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.